To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma.
Clin Cancer Res
; 30(4): 649-651, 2024 02 16.
Article
em En
| MEDLINE
| ID: mdl-38064245
ABSTRACT
Dedifferentiated liposarcoma (DDLPS) has an appealing therapeutic target due to its CDK4 amplification on chromosome 12q. The understanding of geroconversion from quiescent cells to senescent cells defines a patient's response to CDK4 inhibitors. This new observation will inform not only the ongoing phase III clinical trial of abemaciclib, but all future clinical trials in DDLPS. See related article by Gleason et al., p. 703.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Lipossarcoma
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article